Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/40360
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- IOC - Artigos de Periódicos [12776]
Metadata
Show full item record
A CRITICAL REVIEW ON CHAGAS DISEASE CHEMOTHERAPY
Trypanosoma cruzi
Quimioterapia
Revisão
Tratamento clínico
Desenvolvimento de drogas
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Medicina Ttopical. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Biologia Celular e Ultraestrutura. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Biologia Celular e Ultraestrutura. Rio de Janeiro, RJ, Brasil.
Abstract
In this “Critical Review” we made a historical introduction of drugs assayed against Chagas disease beginning
in 1912 with the works of Mayer and Rocha Lima up to the experimental use of nitrofurazone. In the beginning of the
70s, nifurtimox and benznidazole were introduced for clinical treatment, but results showed a great variability and
there is still a controversy about their use for chronic cases. After the introduction of these nitroheterocycles only a
few compounds were assayed in chagasic patients. The great advances in vector control in the South Cone countries,
and the demonstration of parasite in chronic patients indicated the urgency to discuss the etiologic treatment during
this phase, reinforcing the need to find drugs with more efficacy and less toxicity. We also review potential targets in
the parasite and present a survey about new classes of synthetic and natural compounds studied after 1992/1993,
with which we intend to give to the reader a general view about experimental studies in the area of the chemotherapy
of Chagas disease, complementing the previous papers of Brener (1979) and De Castro (1993).
Keywords in Portuguese
Doença de ChagasTrypanosoma cruzi
Quimioterapia
Revisão
Tratamento clínico
Desenvolvimento de drogas
Share